2021
P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).
Schuetze S, Ballman K, Ganjoo K, Davis E, Morgan J, Tinoco G, Burgess M, Van Tine B, Choy E, Shepard D, Kelly C, Riedel R, von Mehren M, Siontis B, Attia S, Schwartz G, Deshpande H, Kozlowski E, Chen H, Rubin B. P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE). Journal Of Clinical Oncology 2021, 39: 11503-11503. DOI: 10.1200/jco.2021.39.15_suppl.11503.Peer-Reviewed Original ResearchObjective response ratePhase 2 trialEpithelioid hemangioendotheliomaObjective responseLarge prospective clinical studiesGI adverse effectsMetastatic epithelioid hemangioendotheliomaObjective tumor progressionPrimary trial endpointNausea/vomitingWeeks of therapyBiomarkers of inflammationProspective clinical studyTreatment of patientsClinical Trials NetworkCommon AEsMedian PFSOS ratesPt ageStable diseasePain scoresAdverse eventsMetastatic diseasePain intensityIndolent growth
2009
A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors
Deshpande H, Gettinger S, Rowen E, Abu-Khalaf M, Clarke J, Burns A, Kelly W. A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors. Journal Of Clinical Oncology 2009, 27: e13501-e13501. DOI: 10.1200/jco.2009.27.15_suppl.e13501.Peer-Reviewed Original ResearchNanoparticle albumin-bound paclitaxelAlbumin-bound paclitaxelCohort 2Cohort 3Cohort 1Platinum agentsSolid tumorsDay 14Common severe adverse eventsGrade 3 anemiaMedian age 51Grade 4 neutropeniaStandard chemotherapy regimenAdvanced solid tumorsPhase 2 studySevere adverse eventsNeurological side effectsCycle 1Stable diseaseChemotherapy regimenDay 1 treatmentAdvanced malignanciesAdverse eventsPartial responseProgressive disease